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Background: This study investigated the effect of exenatide on the cardiac expression of adiponectin receptor 1 and
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits and heart function in streptozotocin-induced
diabetic rats.
Methods: Male Sprague–Dawley rats were randomly divided into four groups, i.e. control group, diabetic group,
diabetic treated with low doses of exenatide (2 μg · kg−1.d−1) and diabetic treated with high doses of exenatide
(10 μg · kg−1.d−1). Diabetes was induced by intraperitoneal injection of streptozotocin (65 mg/kg body weight). At the
termination after exenatide treatment for eight weeks, following anesthesia of the rats, a catheter was inserted into the
left ventricle through the right common carotid artery for measurement of left ventricular pressure, which included left
ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVEDP) and the maximal rate of rise and
decline of ventricular pressure (±dp/dt[max]). Plasma and myocardial adiponectin levels, and the expressions of
myocardial adiponectin receptor 1, p22phox, NADPH oxidase 4 (NOX4), glucose transporter type 4 (Glut4),
AMPK-α, phosphorylated-AMPK-α, connective tissue growth factor (CTGF) and copper zinc superoxide dismutase
(Cu-Zn-SOD) were assayed.
Results: Heart function, plasma adiponectin levels, the protein expression of myocardial phosphorylated-AMPK-α,
the mRNA expression of myocardial Glut4, and the positive expression of myocardial Cu-Zn-SOD were significantly
decreased in diabetic. The protein expression of myocardial adiponectin receptor 1, the mRNA expression of myocardial
p22phox and NOX4, and the positive expression of myocardial CTGF were significantly increased in diabetic. Low and
high doses of exenatide treatment significantly attenuated these changes in diabetic rats.
Conclusions: These results suggest that exenatide may contribute to the improvement of the heart function in diabetic
rats by down-regulating the expression of myocardial adiponectin receptor 1, p22phox and NOX4, and up-regulating
plasma adiponectin level and the expression of myocardial AMPK-α, Glut4 and Cu-Zn-SOD.
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Cardiovascular disease is one of the major complications
of diabetes, resulting in a high risk of morbidity and
mortality and causing significant burden for the health-
care system [1]. Glucagon-like peptide-1 (GLP-1) is an
incretin hormone secreted by intestinal L-cells in re-
sponse to nutrient ingestion [2]. The main physiological
role of GLP-1 is to improve glycemic control by indu-
cing glucose-dependent stimulation of insulin secretion
and suppressing glucagon secretion [2]. Recently, in-
creasing evidences indicate that GLP-1 may play a wide
range of cardiovascular protective roles mediated by
GLP-1 receptor in cardiovascular tissues [3-6].
Adiponectin and its receptors expressed in the heart
may have important functions in the regulation of the
cardiac function and/or metabolism [7,8]. Our previous
studies [9-12] showed that the expression of myocardial
adiponectin receptors were increased in type 1 diabetic
rats and decreased in type 2 diabetic rats. Telmisartan
and rosiglitazone treatment improved the heart function
by upregulating the expression of adiponectin receptors
in the heart of type 2 diabetic rats. It is unknown
whether GLP-1 treatment can improve the heart func-
tion by regulating the expression of adiponectin recep-
tors in the heart of diabetic rats.
Oxidative stress has been suggested to be involved in
the development and progression of diabetes-induced
cardiomyopathy [13]. Activation of nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase seems to be
involved in the elevated oxidative stress in diabetes [14].
NADPH oxidase consists of the membrane-associated
subunits (gp91phox and p22phox) and the cytosolic sub-
units (p47phox, p40phox, p67phox and Rac) [15]. Our
previous studies [10,11,16] showed that the expression
of NADPH oxidase subunits were increased in the heart
of diabetic rats. N-acetylcysteine, telmisartan and rosigli-
tazone treatments inhibit the myocardial expression of
NADPH oxidase subunits, which may result in the im-
provement of heart function in diabetic rats [10,11,16].
It is unknown whether GLP-1 treatment can downregu-
late the expression of NADPH oxidase subunits, p22phox
and NOX4, in the heart of diabetic rats.
The primary aim of this study was to explore whether
GLP-1 produced protective effects on the heart of diabetic
rats independent of its glycemic control effect. The second-
ary aim of this study was to investigate the effect of GLP-1
on the expression of adiponectin receptors and NADPH
oxidase subunits in the heart of a diabetic rat model.
Methods
Induction of diabetes
Forty-two male Sprague–Dawley rats aged 6 weeks,
weighing 140-180 g, and purchased from the experimen-
tal animal center of Shanxi Medical University (Taiyuan,Shanxi, China), were used in the study ([Batch number
of rats: SCXK (Jin) 2009–0001)]. All rats were housed in
a temperature-controlled room (22-24°C) and kept on
12/12 hour light/dark cycles. They had free access to
standard rat chow and water. All animals received humane
care in accordance with the principles of the Chinese
Council on Animal Care and the experimental protocol
was approved by the Institutional Animal Care and Use
Committee of Shanxi Medical University of China. After
one week’s adaptation, all rats were randomly divided into
2 groups: a control group (C, n = 7) and a diabetic group
(n = 35). Diabetic rats were given the peritoneal injection
of a single dose of streptozotocin (65 mg/kg body weight;
Sigma, St. Louis, MO, USA), while the control group was
given equivalent volume of citric acid buffer. At 72 hr after
streptozotocin injection, blood glucose was tested and rats
with glucose levels greater than 16.7 mmol/L were consid-
ered as diabetic. There were 29 rats induced of diabetes.
Diabetic rats were randomly divided into the diabetic
group (D, n = 10), diabetic treated with low dose of exena-
tide (DTL, n = 10) and diabetic treated with high dose of
exenatide (DTH, n = 9). Rats treated with low dose of
exenatide were injected subcutaneously with exenatide in
dose of 1 μg · kg−1 twice daily for 8 weeks. Rats treated
with high dose of exenatide were injected subcutaneously
with exenatide in the dose of 5 μg · kg−1 twice daily for
8 weeks. Control and diabetic rats were injected subcuta-
neously with equivalent volume of normal saline for
8 weeks. On 1 day before the experiments were termi-
nated, all animals were weighed, fasted for 12–14 h, and
then anesthetized with an intraperitoneal injection of 10%
chloral hydrate (0.3 mL/100 g body weight), with efforts
taken to reduce animal suffering. The heart function was
measured by carotid artery cannula. The rats were sacri-
ficed after blood sample had been drawn from abdominal
cardinal vein. The blood samples were centrifuged and
plasma aliquots were stored at −80°C until assays were
done. The heart was immediately taken out of thoracic
cavity after the rat was sacrificed. The heart was rinsed
with normal saline, dried with filter-paper, and then
weighed. The ratio of heart weight to body weight was
calculated. The apex of heart was fixed in 10% neutral
buffered formalin and processed for histological ana-
lysis. The rest part of cardiac ventricle was immedi-
ately placed into the liquid nitrogen and then stored in
the –80°C refrigerator until analyses were performed.
Measurement of cardiac function
Following anesthesia of the rats with an intraperitoneal
injection of 10% chloral hydrate (0.3 ml/100 g body
weight), the neck skin was cut open and the right common
carotid artery was fully exposed. A micromanometer-
tipped catheter was inserted into the left ventricle through
the right common carotid artery for measurement of left
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(LVSP), left ventricular end-diastolic pressure (LVEDP)
and the maximal rate of rise and decline of ventricular
pressure (±dp/dt[max]) were obtained by BL-410 Bio-signal
analysis system (Chengdu TME Technology Co. Ltd,
Sichuan, China).
Plasma analytical procedures
The plasma glucose level was measured by the glucose
oxidase method. Plasma cholesterol, triglyceride and free
fatty acid were measured colorimetrically using commer-
cially available kit (Zhejiang Dong’ou Diagnostic Products
Co. Ltd., Zhejiang, China; Nanjing Built Technology Co.
Ltd., Jiangsu, China). Plasma adiponectin was measured
using a commercially available ELISA kit (Westang
Biotechnology Co., Ltd, Shanghai, China). Plasma insulin
was measured using a commercially available radio-
immunoassay kit (Beijing Kemei Biological Technology
Co., Ltd., Beijing, China).
Determination of cardiac adiponectin
Frozen heart tissue was pulverized and homogenized at
4°C in cold buffer (20 mM Tris–HCl, pH 7.5, 50 mM
2-mercaptoethanol, 5 mM EGTA, 2 mM EDTA, 1 mM
PMSF, 10 mM NaF, 25 μg/ml leupeptin, 2 μg/ml aproti-
nin) and then centrifuged at 1500 g for 5 minutes at 4°C.
The supernatant was collected and stored at −80°C until
analyses were conducted. The protein content of the
samples was measured using the Bradford protein assay
[17] with the use of bovine serum albumin as the con-
centration standard. Cardiac adiponectin was measured
using a commercially available enzyme-linked immuno-
sorbent assay (ELISA) kit (Westang Biotechnology Co.,
Ltd, Shanghai, China).
Morphological study
Tissues fixed in 10% buffered formalin were embedded
in paraffin, sectioned at 4 μm thickness and stained with
hematoxylin and eosin (HE) for light microscopic mor-
phological study.
Immunohistochemical analysis of adiponectin receptor 1,
CTGF and Cu-Zn-SOD
Ventricular samples were immediately fixed in 10% neu-
tral buffered formalin overnight and embedded in paraf-
fin. Paraffin embedded tissue blocks were sectioned at
3 μm and sections were mounted on positively charged
slides. The slides were deparaffinized, rehydrated, blocked
with 3% hydrogen peroxide [to block endogenous peroxid-
ase activity, then washed with phosphate-buffered saline
(PBS)], and blocked with 5% normal goat serum in PBS
for 30 min. The slides were subsequently incubated with
primary rabbit polyclonal adiponectin receptor 1 (1:400)
antibody (Beijing Biosynthesis Biotechnology Co., Ltd,Beijing, China), connective tissue growth factor antibody
(1:100, Wuhan Boster Biological Engineering Company
Limited, Hubei, China), copper zinc superoxide dismutase
(Cu-Zn-SOD) antibody (1:400, Wuhan Boster Biological
Engineering Company Limited, Hubei, China) in PBS
containing 1% normal goat serum overnight at 4°C. The
primary antibody was rinsed off with PBS, and the sec-
tions were incubated with biotin labeling goat anti-rabbit
secondary antibodies (1:100, Wuhan Boster Biological
Engineering Company Limited, Hubei, China) for 30 min.
After three washing steps in PBS were completed, the
sections were stained using horseradish enzyme labeling
strepto-avidin solution (1:100, Wuhan Boster Biological
Engineering Company Limited, Hubei, China) for 10 min,
washed with PBS, dyed with 3, 3′-diaminobenzidine
(DAB), and washed with distilled water. The sections
were counterstained using hematoxylin, washed in run-
ning water, dehydrated through a series of increasing
alcohol concentrations, and cleared in xylene before being
mounted in resinous mounting medium with coverslips.
Some sections incubated with nonspecific rabbit immuno-
globulins (IgG) served as negative controls. Quantification
was performed with the observer blinded to details. With
the use of high power microscope, all slides were observed
and photographed. An average of five fields under micro-
scope (×400) in each slice was randomly selected, and the
average value of gray scale which had an inverse propor-
tion to the positive stained intensity was quantified using
BI-2000 color image processing system (Chengdu TME
Technology Co., Ltd, Sichuan, China).
Real-time fluorescence quantitative PCR analysis for
p22phox, NOX4 and Glut4
Total RNA extraction was performed using Trizol reagent
(Sangon Biotech Co., Ltd, Shanghai, China) according to
the manufacturer’s recommendations. DNA was synthe-
sized from total RNA and then was amplified using a
RT-PCR reagent kit (Fermentas China Co., Ltd, Shenzhen,
China). Real-time quantitative polymerase chain reaction
was performed with 50 μl reaction volumes containing
25 μl 2 × FastStart Universal SYBR Green Master Mix
(Roche Ltd., Basel, Switzerland), 1 μl 0.3 μM of each
primer, 5 μl of cDNA template, and 19 μl deionized
water. Primer sequences are described in Table 1. PCR
amplification was done on a real-time fluorescence quan-
titative PCR detection system (Xi’an Tianlong Science and
Technology Co., Ltd, Xi’an, China) using the following
parameters: initial denaturation at 95°C for 10 min,
followed by 40 cycles of denaturation at 94°C for 30 sec-
onds, annealing at 58°C for 30 seconds, and extension at
72°C for 45 seconds. Relative gene expression levels were
quantified using the comparative ΔCt (cycle threshold)
method. This method normalizes Ct values of the detected
gene to the average of that of the housekeeping genes and







Forward 5′- GATGCCGTCGGGTTTCCAGCA -3′ 233 bp
Reverse 5′- TGAGGGTGCCTTGTGGGATGG -3′
NOX4
Forward 5′-TCTAGGCCGTAACGGAATTC-3′ 245 bp
Reverse 5′-TGTAACCATGAGGAACAATACCACC-3′
p22phox
Forward 5′-CTCTATTGTTGCAGGAGTGC-3′ 457 bp
Reverse 5′-TCACACGACCTCATCTGTCAC-3′
β-actin
Forward 5′-GTCAGGTCATCACTATCGGCAAT-3′ 147 bp
Reverse 5′-AGAGGTCTTTACGGATGTCAACGT-3′
Glut4: glucose transporter type 4.
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the control. Data analysis was performed using the 2-ΔΔCt
method [18].Western blotting analysis for adiponectin receptor 1,
AMPK-α and phosphor-AMPK-α
Heart tissue (100 mg) was pulverized and homogenized
using a Polytron homogenizer in 1.5 ml cold lysis buffer
as described in Section 2.4. The homogenate was centri-
fuged at 15,000 g for 20 min at 4°C and the supernatant
was collected. The protein content of the supernatant
was measured using the Bradford protein assay [17]. Ali-
quot samples were stored at −80°C until use.
After boiling at 95°C for 5 min, samples (50 μg pro-
tein/lane) were loaded to 10-15% SDS-PAGE gel and
then transferred to nitrocellulose membranes. The mem-
branes were blocked in 5% non-fat milk in TBST (0.05%
Tween-20 in 1 × Tris-buffered saline (TBS) and then in-
cubated with primary antibodies of: adiponectin receptor
1 (1:1000) ( Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA); AMPK-α and phosphor-AMPK-α (1:1000) (Cell
Signalling Technology, Beverly, MA, USA). The mem-
branes were washed and then incubated with a secondary
horseradish peroxidase-conjugated anti-rabbit IgG anti-
body (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA). Proteins were visualized by 3, 3′-diaminobenzidin
(DAB) (Zhongshan Goldenbridge Biotechnology Co., Ltd,
Beijing, China) and quantified using image analysis soft-
ware. In all instances, the membranes were stained with
Ponceau stain and reblotted with antibody against β-actin
(1:1000, Santa Cruz Biotechnology Inc., Santa Cruz, USA)
after stripping to verify the uniformity of protein load and
the transfer efficiency across the test samples.Statistical analysis
Data are expressed as means ± S.E.M. Statistical analysis
was performed by one –way ANOVA followed by the




The levels of plasma glucose, total cholesterol, triglycer-
ides and free fatty acids were significantly increased, and
the level of plasma insulin was significantly decreased in
diabetic rats compared to controls (P<0.05). There was
no significant difference in plasma glucose, total choles-
terol, triglycerides, free fatty acids and insulin between
diabetic rats treated with low dose of exenatide and un-
treated diabetic rats (P>0.05). The levels of plasma total
cholesterol, triglycerides and free fatty acids were sig-
nificantly decreased in diabetic treated with high dose
of exenatide compared to diabetic untreated (P<0.05).
However, there was no significant difference in plasma
glucose and insulin between diabetic treated with high
dose of exenatide and diabetic untreated (P>0.05). The
levels of plasma free fatty acids were significantly de-
creased in diabetic treated with high dose of exenatide
compared to diabetic treated with low dose of exenatide
(P<0.05). However, there was no significant difference
in plasma glucose, total cholesterol, triglycerides and
insulin between diabetic treated with low dose of exe-
natide and diabetic treated with high dose of exenatide
(P>0.05). The ratio of heart weight to body weight, as an
index of cardiac hypertrophy, was significantly increased
in diabetic rats compared to controls (P<0.05). Low or
high doses of exenatide treatment did not attenuate the
increased ratio of heart weight to body weight in diabetic
rats (P>0.05) (Table 2).
Histological changes
The results of the myocardium stained by hematoxylin
and eosin (HE) and observed through the light micro-
scope in diabetic rats were as following: The myocardial
cells lined up in order, the sizes of cellular nucleus were
consistent, and the cytoplasm was stained in uniformity
in control rats. The myocardial cells lined up in disorder,
the sizes of cellular nucleus were inconsistent, and the
myocardial fibers were broken and lined up in disorder
in diabetic rats. The pathological changes were obviously
alleviated in diabetic rats treated with low and high
doses of exenatide than those in diabetic rats untreated.
The myocardial cells lined up comparatively in order,
the sizes of cellular nucleus were comparatively consist-
ent, and there was no obviously broken myocardial fiber
in diabetic rats treated with low and high doses of
exenatide than those in diabetic rats untreated. The
pathological changes were further alleviated in diabetic
Table 2 General characteristics in control, diabetic, and diabetic treated with low and high doses of exenatide
C D DTL DTH
Number 7 10 10 9
Plasma glucose (mM) 4.31 ± 0.72 29.86 ± 1.32* 29.08 ± 1.20* 28.66 ± 0.89*
Plasma Insulin (Iu/ml) 19.36 ± 0.58 4.91 ± 0.27* 5.06 ± 0.30* 5.19 ± 0.31*
Plasma total cholesterol (mM ) 1.46 ± 0.38 2.79 ± 0.29* 2.77 ± 0.50* 2.27 ± 0.72a*,#
Plasma triglycerides (mM ) 0.83 ± 0.13 1.42 ± 0.20* 1.29 ± 0.27* 1.08 ± 0.87#
Plasma free fatty acid (mM ) 1.45 ± 0.20 2.60 ± 0.41* 2.26 ± 0.63* 1.53 ± 0.34#,$
Body weight (g) 459.57 ± 86.52 207.70 ± 48.89* 200.60 ± 74.48* 211.11 ± 41.20*
Heart weight (g) 1.30 ± 0.17 0.93 ± 0.29* 0.85 ± 0.20* 0.88 ± 0.23*
Heart/body weight (g/kg) 2.86 ± 0.38 4.50 ± 0.68* 4.42 ± 0.76* 4.42 ± 0.86*
Values were obtained at sacrifice, after administration with or without 8 weeks of exenatide treatment. Control (C), diabetic (D), diabetic treated with low dose
(2 μg · kg−1.d−1) of exenatide (DTL), diabetic treated with high dose (10 μg · kg−1.d−1) of exenatide (DTH). All values were expressed as mean ± S.E.M. *P < 0.05 or
0.01 vs. C; #P < 0.05 vs. D; $P < 0.05 vs. DTL.
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diabetic rats treated with low dose of exenatide (Figure 1).Heart function
Compared to controls, left ventricular systolic pressure
(LVSP), +dp/dtmax and -dp/dtmax were significantly re-
duced and left ventricular end-diastolic pressure (LVEDP)
was significantly increased in diabetic rats, indicating that
the heart function was significantly decreased in diabetic
rats. The high and low doses of exenatide treatment
significantly attenuated these changes in diabetic rats.
Compared to diabetic rats treated with low dose of
exenatide, diabetic rats treated with high dose of exena-
tide had significant increased LVSP and decreased
LVEDP (P<0.05). There was no significant difference
in + dp/dtmax and -dp/dtmax between diabetic rats treated
with low dose of exenatide and diabetic rats treated with
high dose of exenatide (Table 3).Immunohistochemical assay
The yellow positive staining of adiponectin receptor 1
was mainly located in myocardial cellular member and
cytoplasm. The expression of adiponectin receptor 1 was
quantified using the average value of gray scale which
was inversely proportional to the positive staining inten-
sity. The average value of gray scale of adiponectin re-
ceptor 1 was significantly decreased in the heart in
diabetic rats compared to controls, indicating that the
positive staining intensity of adiponectin receptor 1 was
significantly increased in the heart in diabetic rats com-
pared to controls. The high and low doses of exenatide
treatment significantly increased the average value of
gray scale of adiponectin receptor 1 in the heart in dia-
betic rats, indicating that exenatide treatment decreased
the positive stained intensity of adiponectin receptor 1
in the heart in diabetic rats. There was no difference in
the expression of cardiac adiponectin receptor 1 betweendiabetic rats treated with low dose of exenatide and dia-
betic rats treated with high dose of exenatide (Figure 2).
The yellow positive staining of CTGF was mainly lo-
cated in myocardial cellular cytoplasm. The CTGF ex-
pression was quantified using the average value of gray
scale which was inversely proportional to the positive
stained intensity. The average value of grey scale of
CTGF was significantly decreased in diabetic rats com-
pared to controls, indicating that the positive stained
intensity of CTGF increased in diabetic rats compared
to controls. The high and low doses of exenatide treat-
ment significantly increased the average value of grey
scale of CTGF in diabetic rats, indicating that exenatide
treatment decreased the positive stained intensity of
CTGF in diabetic rats. The average value of grey scale of
CTGF was significantly increased in diabetic rats treated
with high dose of enenatide compared to diabetic rats
treated with low dose of enenatide, indicating that the
positive stained intensity of CTGF decreased in high
dose of enenatide treatment compared to low dose of
enenatide treatment (Figure 3).
The yellow positive staining of Cu-Zn-SOD was mainly
located in myocardial cellular cytoplasm. The Cu-Zn-SOD
expression was quantified using the average value of gray
scale which was inversely proportional to the positive
stained intensity. The average value of gray scale of
Cu-Zn-SOD was significantly increased in the heart in dia-
betic rats compared to controls, indicating that the posi-
tive stained intensity of Cu-Zn-SOD decreased in the
heart in diabetic rats compared to controls. The high and
low doses of exenatide treatment significantly decreased
the average value of gray scale of Cu-Zn-SOD in the heart
in diabetic rats, indicating that exenatide treatment in-
creased the positive stained intensity of Cu-Zn-SOD in
the heart in diabetic rats. There was no difference in the
expression of cardiac Cu-Zn-SOD between diabetic rats
treated with low dose of exenatide and diabetic rats
treated with high dose of exenatide (Figure 4).
Figure 1 Representative slides showing HE staining in the myocardium. Slides A, B, C, D represent control, diabetic, diabetic treated with
low dose (2 μg · kg−1.d−1) of exenatide and diabetic treated with high dose (10 μg · kg−1.d−1) of exenatide, respectively. Magnifications × 400.
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Plasma adiponectin levels were significantly decreased in
diabetic rats compared to controls. The high and low
doses of exenatide treatment significantly increased plasma
adiponectin levels in diabetic rats. There was no significant
difference in plasma adiponectin levels between diabetic
rats treated with low dose of exenatide and diabetic rats
treated with high dose of exenatide. There was no signifi-
cant difference in the myocardial adiponectin levels among
the four groups (Table 3).Table 3 Heart function, plasma and myocardial adiponectin le
and high doses of exenatide
C
Number 7
LVSP (mmHg) 142.48 ± 11.01
LVEDP (mmHg) 6.5 ± 1.42
+dp/dtmax (mmHg.s−1) 7780.51 ± 809.47 2
-dp/dtmax (mmHg.s−1) 7014.15 ± 746.47 1
Plasma adiponectin (ng/ml) 1877.96 ± 377.97 1
Myocardial adiponectin (ng/μg protein) 0.13 ± 0.04
Values were obtained at sacrifice, after administration with or without 8 weeks of e
(2 μg · kg−1.d−1) of exenatide (DTL), diabetic treated with high dose (10 μg · kg−1.d−1
ventricular end diastolic pressure; −dp/dtmax: the maximum descent-speed of pres
maximum ascendent-speed of pressure in isovolumic contraction period in the left
C; #P < 0.05 vs. D; $P < 0.05 vs. DTL.Myocardial protein expression of adiponectin receptor 1
The protein expression of myocardial adiponectin recep-
tor 1 significantly increased in diabetic rats compared to
controls. The high and low doses of exenatide treatment
significantly decreased the protein expression of myocar-
dial adiponectin receptor 1 in diabetic rats. There was
no difference in the protein expression of myocardial
adiponectin receptor 1 between diabetic rats treated
with low dose of exenatide and diabetic rats treated with
high dose of exenatide (Figure 5).vels in control, diabetic, and diabetic treated with low
D DTL DTH
10 10 9
78.77 ± 14.56* 90.25 ± 10.67*,# 102.42 ± 9.32*,#,$
11.2 ± 1.68* 9.58 ± 3.18*,# 7.28 ± 2.61#,$
182.12 ± 344.15* 3735.14 ± 384.41*,# 3892.61 ± 535.43*,#
838.39 ± 206.33* 3774.86 ± 419.87*,# 3997.33 ± 782.37*,#
032.33 ± 170.23* 1387.72 ± 343.71# 1396.82 ± 185.52#
0.11 ± 0.03 0.13 ± 0.06 0.16 ± 0.05
xenatide treatment. Control (C), diabetic (D), diabetic treated with low dose
) of exenatide (DTH). LVSP: left ventricular systolic pressure; LVEDP: left
sure in isovolumic relaxation period in the left ventricle; +dp/dtmax: the
ventricle. All values were expressed as mean ± S.E.M. *P < 0.05 or 0.01 vs.





































Figure 2 Top panel: representative slides showing immunohistochemical staining of adiponectin receptor 1 (AdipoR1) (stained in
brown as shown by arrow) in the myocardium. Slides A, B, C, D represent control, diabetic, diabetic treated with low dose (2 μg · kg−1.d−1) of
exenatide and diabetic treated with high dose (10 μg · kg−1.d−1) of exenatide, respectively. Magnifications × 400. Bottom: bar graph shows
quantitative analysis of myocardial adipoR1 expression in control, diabetic and diabetic treated with low (2 μg · kg−1.d−1) or high (10 μg · kg−1.d−1)
dose of exenatide. The adiponectin receptor 1 (adipoR1) expression was quantified using the average value of gray scale which had an inverse
proportion to the positive stained intensity. Control (C, n = 7), diabetic (D, n = 10), diabetic treated with low dose (2 μg · kg−1.d−1) of exenatide
(DTL, n = 10), diabetic treated with high dose (10 μg · kg−1.d−1) of exenatide (DTH, n = 9). Data are expressed as mean ± S.E.M. *P < 0.05 different
from control, #P < 0.05 different from diabetic.
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expression
The level of myocardial phosphorylation of AMPK-alpha
(Thr172) was significantly decreased in diabetic rats
compared to controls. The high and low doses of exena-
tide treatment significantly increased the level of myo-
cardial phosphorylation of AMPK-alpha (Thr172) in
diabetic rats. There was no difference in the level of myo-
cardial phosphorylation of AMPK-alpha (Thr172) betweendiabetic rats treated with low dose of exenatide and dia-
betic rats treated with high dose of exenatide (Figure 6).
Myocardial mRNA expression of Glut4
The mRNA expression of myocardial Glut4 was signifi-
cantly decreased in diabetic rats compared to controls.
The high and low doses of exenatide treatment signifi-
cantly increased the mRNA expression of myocardial
Glut4 in diabetic rats. There was no difference in the
BDC
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Figure 3 Top panel: representative slides showing immunohistochemical staining of connective tissue growth factor (CTGF) (stained in
brown as shown by arrow) in the myocardium. Slides A, B, C, D represent control, diabetic, diabetic treated with low dose (2 μg · kg−1.d−1) of
exenatide and diabetic treated with high dose (10 μg · kg−1.d−1) of exenatide, respectively. Magnifications × 400. Bottom: bar graph shows
quantitative analysis of myocardial CTGF expression in control, diabetic and diabetic treated with low (2 μg · kg−1.d−1) or high (10 μg · kg−1.d−1) dose of
exenatide. The CTGF expression was quantified using the average value of gray scale which had an inverse proportion to the positive stained intensity.
Control (C, n = 7), diabetic (D, n = 10), diabetic treated with low dose (2 μg · kg−1.d−1) of exenatide (DTL, n = 10), diabetic treated with high
dose (10 μg · kg−1.d−1) of exenatide (DTH, n = 9). Data are expressed as mean ± S.E.M. *P < 0.05 different from control, #P < 0.05 different from
diabetic, $P < 0.05 different from diabetic treated with low dose (2 μg · kg−1.d−1) of exenatide.
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http://www.dmsjournal.com/content/6/1/29mRNA expression of myocardial Glut4 between diabetic
rats treated with low dose of exenatide and diabetic rats
treated with high dose of exenatide (Figure 7).
Myocardial mRNA expression of p22phox and Nox4
The mRNA expression of myocardial p22phox and Nox4
was significantly increased in diabetic rats compared tocontrols. The high and low doses of exenatide treatment
significantly decreased the mRNA expression of myo-
cardial p22phox and Nox4 in diabetic rats. The mRNA
expression of myocardial p22phox and Nox4 was sig-
nificantly decreased in diabetic rats treated with high
dose of enenatide compared to diabetic rats treated with















































Figure 4 Top panel: representative slides showing immunohistochemical staining of copper zinc superoxide dismutase (Cu-Zn-SOD)
(stained in brown as shown by arrow) in the myocardium. Slides A, B, C, D represent control, diabetic, diabetic treated with low dose
(2 μg · kg−1.d−1) of exenatide and diabetic treated with high dose (10 μg · kg−1.d−1) of exenatide, respectively. Magnifications × 400. Bottom: bar
graph shows quantitative analysis of myocardial Cu-Zn-SOD expression in control, diabetic and diabetic treated with low (2 μg · kg−1.d−1) or high
(10 μg · kg−1.d−1) dose of exenatide. The Cu-Zn-SOD expression was quantified using the average value of gray scale which had an inverse proportion
to the positive stained intensity. Control (C, n = 7), diabetic (D, n = 10), diabetic treated with low dose (2 μg · kg−1.d−1) of exenatide (DTL, n = 10),
diabetic treated with high dose (10 μg · kg−1.d−1) of exenatide (DTH, n = 9). Data are expressed as mean ± S.E.M. *P < 0.05 different from
control, #P < 0.05 different from diabetic.
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In the present study, we showed that exenatide exerted
protective effects on the heart through antioxidative
actions and regulation effect on adiponectin and its
receptors without lowering the blood glucose level in a
streptozotocin-induced rat model of type 1 diabetes.
This is the first report of a GLP-1 receptor agonist maycontribute, via its regulation effect on adiponectin recep-
tors, to amelioration of heart function in diabetic rats.
Glucagon like peptide 1 (GLP-1) is one of the incretin
secreted by intestinal L cell. GLP-1 receptor is distrib-
uted widely across different tissues. In addition to the
pancreas, GLP-1 receptor is also expressed in the lung,
brain, kidney, and heart, etc. [19]. In the heart, GLP-1


































Figure 5 Western blot analysis of myocardial protein expression
of adiponectin receptor 1 (AdipoR1) in control, diabetic and
diabetic treated with low (2 μg · kg−1.d−1) or high dose
(10 μg · kg−1.d−1) of exenatide. Equal protein loading was confirmed
with β-actin. Mean band density was normalized relative to β-actin.
Control (C, n = 7), diabetic (D, n = 10), diabetic treated with low dose
(2 μg · kg−1.d−1) of exenatide (DTL, n = 10), diabetic treated with high
dose (10 μg · kg−1.d−1) of exenatide (DTH, n = 9). Data are expressed as
mean ± S.E.M. *P < 0.05 different from control, #P < 0.05 different
from diabetic.









































Figure 6 Western blot analysis of renal protein expression of
phospho-AMPK- alpha (Thr172) and AMPK-alpha in control,
diabetic and diabetic treated with low (2 μg · kg−1.d−1) or high
(10 μg · kg−1.d−1) dose of exenatide. Equal protein loading was
confirmed with β-actin. Mean band density was normalized relative
to β-actin. Control (C, n = 7), diabetic (D, n = 10), diabetic treated
with low dose (2 μg · kg−1.d−1) of exenatide (DTL, n = 10), diabetic
treated with high dose (10 μg · kg−1.d−1) of exenatide (DTH, n = 9).
Data are expressed as mean ± S.E.M. *P < 0.05 different from control,
#P < 0.05 different from diabetic.
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http://www.dmsjournal.com/content/6/1/29receptor is distributed in the cardiomyocyte, endocar-
dium, microvascular endothelium and coronary smooth
muscle cells. GLP-1 receptor plays an important role
in maintaining the normal myocardial structure and
physiological function [20]. Mice with genetic deletion
of the GLP-1 receptor (GLP-1R (−/−)) exhibit elevated
left ventricular end diastolic pressure, increased left ven-
tricular thickness, and impaired left ventricular contract-
ility and diastolic function, indicating that an essential
role for GLP-1 receptor in the control of murine cardiac
structure and function in vivo [21]. Many studies showed
that GLP-1 improved heart function and played a pro-
tective role on the cardiovascular system by binding with
the GLP-1 receptor expressed in the cardiovascular tis-
sue [21-27]. Our study showed that the levels of blood
glucose and lipids were significantly increased and the
heart function was deteriorated in diabetic rats. GLP-1
receptor agonist exenatide decreased the level of blood
lipids, improved the heart function, and alleviated the
myocardial pathological lesion, but did not affect the
level of blood glucose, suggesting that GLP-1 receptor
agonist could produce the protective effect on the heart
of diabetic rats independent of its hypoglycemic effect.
The reason why exenatide had no effect on reducing
blood glucose in type 1 diabetic rats in the current studywas that exenatide did not restore insulin secretion in
our model as shown in Table 2. Our results are in agree-
ment with the results of a previous study [28] showing
that GLP-1 receptor agonist had no effect on reducing
blood glucose in a rat model of type 1 diabetes.
Adiponectin is an adipocyte-derived protein with anti-
inflammatory, anti-diabetic and anti-atherogenic properties.
Adiponectin is also synthesized and secreted by human
and murine cardiomyocytes [7,8]. Plasma adiponectin level
was reported to be significantly increased in the spontan-
eously hypertensive, heart failure-prone rats after GLP-1
treatment for 3 months [26]. The present study showed
that GLP-1 receptor agonist exenatide significantly in-
creased the level of plasma adiponectin, but had no effect
on the myocardial adiponectin levels in diabetic rats. It
was reported that GLP-1 receptor agonist exenatide could
directly induce adiponectin expression and promote adi-
ponectin secretion in 3 T3-L1 adipocytes [29]. Therefore,
the mechanism that GLP-1 increases the plasma adipo-
nectin level may be related to direct stimulation of the
synthesis and secretion of adiponectin in adipocytes.







































































Figure 8 Real-time fluorescence quantitative polymerase chain
reaction (PCR) analysis of myocardial mRNA expression of
p22phox (A) and NOX4 (B) in control, diabetic and diabetic
treated with low (2 μg · kg−1.d−1) or high (10 μg · kg−1.d−1) dose
of exenatide. Relative gene expression levels were normalized
relative toβ-actin. Control (C, n = 7), diabetic (D, n = 10), diabetic
treated with low dose (2 μg · kg−1.d−1) of exenatide (DTL, n = 10),
diabetic treated with high dose (10 μg · kg−1.d−1) of exenatide
(DTH, n = 9). Data are expressed as mean ± S.E.M. *P < 0.05 different
from control, #P < 0.05 different from diabetic, $P < 0.05 different
from diabetic treated with low dose (2 μg · kg−1.d−1) of exenatide.

































Figure 7 Real-time fluorescence quantitative polymerase chain
reaction (PCR) analysis of myocardial mRNA expression of glucose
transporter type 4 (Glut4) in control, diabetic and diabetic treated
with low (2 μg · kg−1.d−1) or high (10 μg · kg−1.d−1) dose of
exenatide. Relative gene expression levels were normalized relative
to β-actin. Control (C, n = 7), diabetic (D, n = 10), diabetic treated
with low dose (2 μg · kg−1.d−1) of exenatide (DTL, n = 10), diabetic
treated with high dose (10 μg · kg−1.d−1) of exenatide (DTH, n = 9).
Data are expressed as mean ± S.E.M. *P < 0.05 different from control,
#P < 0.05 different from diabetic.
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http://www.dmsjournal.com/content/6/1/29Adiponectin plays its role by binding to its receptors 1
and 2, both are expressed in myocardial tissues [7]. The
current study showed that both high and low doses of
exenatide treatment could significantly decrease the ex-
pression of myocardial adiponectin receptor 1 in diabetic
rats. There was no significant difference in the expres-
sion of myocardial adiponectin receptor 1 between dia-
betic rats treated with high and low doses of exenatide.
To our knowledge, this is the first report that the
expression of myocardial adiponectin receptor 1 was
reduced by GLP-1 analogue in diabetic rats. Exenatide
may exert its protective effect on the heart of diabetic
rats by increasing plasma adiponectin level and decreas-
ing the expression of myocardial adiponectin receptor 1.
Adiponectin can improve glucose metabolism by bind-
ing to its receptor and activating the adenosine mono-
phosphate–activated protein kinase (AMPK) signaling
pathway [30]. AMPK increases myocardial glucose up-
take and utilization through different mechanisms in-
cluding stimulating the translocation of Glut4 to the
sarcolemma in the heart [31]. AMPK deficiency has been
reported to be associated with depressed cardiac func-
tion in mice [32]. GLP-1 treatment resulted in enhanced
phoshorylation of AMPK in normoxic, perfused hearts
[33]. Dipeptidyl peptidase IV inhibitor upregulates Glut4
translocation and expression in heart of spontaneously
hypertensive rats [34]. This study shows that exenatide
treatment increases the level of phosphorylation of AMPK
and the mRNA expression of Glut4 in the heart of diabetic
rats. The increased adiponectin may partially explain the
increased phosphorylation of AMPK and Glut4, which
might contribute to the ameliorated heart function in
diabetic rats treated with exenatide.An imbalance between reactive oxygen species gener-
ation and antioxidant capacity favors the former causing
oxidative stress and oxidative damage [35]. Oxidative
stress has been suggested to be involved in the develop-
ment and progression of diabetes-induced cardiomyop-
athy [10,11,13,16]. Nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase is the main source of reactive
oxygen species in the cardiovascular tissues [36]. NADPH
oxidase subunits include Nox1-5, p22phox, p47phox, p67phox,
and Rac [37]. Activation of NAD(P)H oxidase seems to be
relevant to the elevated oxidative stress in diabetes [14]. It
was reported that GLP-1 decreased reactive oxygen species
production and the levels of NADPH oxidase such as p47
(phox), gp91(phox), p22(phox) and p40(phox) in high-
glucose–induced cardiac microvascular endothelial cells
[38]. Glucagon-like peptide-1 receptor (GLP-1R) agonist
exendin-4 ameliorated myocardial oxidative stress via sup-
pression of NADPH oxidase 4 with concomitant elevation
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http://www.dmsjournal.com/content/6/1/29of antioxidants (SOD-1 and glutathione peroxidase) in type
2 diabetic mice [39]. The present study showed that GLP-1
analogue exenatide reduces the expression of myocardial
p22phox, Nox4 and CTGF, increases the expression of
myocardial Cu-Zn-SOD, alleviates the myocardial patho-
logical lesion, and improves the heart function. Exenatide
can significantly reduce the myocardial oxidative stress and
oxidative damage, and produce a protective effect on the
heart in diabetic rats.
It is well known that exenatide is effective on reducing
body weight as it has been shown to do in models of
type 2 diabetes. However, the current study showed that
exenatide treatment did not reduce the body weight in
a streptozotocin-induced rat model of type 1 diabetes.
Therefore, the decreased expressions of myocardial adi-
ponectin receptor and NAPDH subunits by exenatide
treatment could not be attributed to the body weight
loss in diabetic rats.
Conlusions
We have shown that long term treatment with exenatide
dose-dependently down-regulates the mRNA expression
of myocardial p22phox and NOX4, dose-independently
down-regulates the expression of myocardial adiponectin
receptor 1, and dose-independently up-regulates the level
of plasma adiponectin and the expression of myocardial
AMPK-α, GLUT4 and Cu-Zn-SOD without lowering
blood glucose in a streptozotocin-induced rat model of
type 1 diabetes. The increase of myocardial glucose oxida-
tion and the decrease of oxidative stress by exematide may
contribute to the improvement of the heart function in
diabetic rats. This study may provide the first evidence
that GLP-1 receptor agonists may contribute to the pre-
vention of diabetic cardiomyopathy via its regulation effect
on adiponectin receptors.
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